CD4+CD25highCD127low regulatory T cells in patients with stable angina and their dynamics after intracoronary sirolimus-eluting stent implantation

Потехина, А В; Проваторов, С И; Sokolov, V O; Pylaeva, Ekaterina; Масенко, В П; Ноева, Е А; Kukhtina, N. B.; Красникова, Т. Л.; Arefieva, T. I.

doi:10.1016/j.humimm.2011.03.015

Cited by 5 publications

(3 citation statements)

References 29 publications

(38 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Mechanistically, RAPA attenuates cell-cycle advancement through inhibitory regulation of the CKI p27 kipa . In another study, RAPA has been demonstrated to increase the expansion of Treg cells, a finding that indicates that RAPA can modulate the adaptive immune response to inhibit AS (Potekhina et al, 2011).…”

Section: Anti-atherosclerotic Effects Of Rapamycinmentioning

confidence: 97%

Rapamycin: A Bacteria-Derived Immunosuppressant That Has Anti-atherosclerotic Effects and Its Clinical Application

et al. 2019

View full text Add to dashboard Cite

Atherosclerosis (AS) is the leading cause of stroke and death worldwide. Although many lipid-lowering or antiplatelet medicines have been used to prevent the devastating outcomes caused by AS, the serious side effects of these medicines cannot be ignored. Moreover, these medicines are aimed at preventing end-point events rather than addressing the formation and progression of the lesion. Rapamycin (sirolimus), a fermentation product derived from soil samples, has immunosuppressive and anti-proliferation effects. It is an inhibitor of mammalian targets of rapamycin, thereby stimulating autophagy pathways. Several lines of evidence have demonstrated that rapamycin possess multiple protective effects against AS through various molecular mechanisms. Moreover, it has been used successfully as an anti-proliferation agent to prevent in-stent restenosis or vascular graft stenosis in patients with coronary artery disease. A thorough understanding of the biomedical regulatory mechanism of rapamycin in AS might reveal pathways for retarding AS. This review summarizes the current knowledge of biomedical mechanisms by which rapamycin retards AS through action on various cells (endothelial cells, macrophages, vascular smooth muscle cells, and T-cells) in early and advanced AS and describes clinical and potential clinical applications of the agent.

show abstract

Section: Anti-atherosclerotic Effects Of Rapamycinmentioning

confidence: 97%

Rapamycin: A Bacteria-Derived Immunosuppressant That Has Anti-atherosclerotic Effects and Its Clinical Application

et al. 2019

View full text Add to dashboard Cite

show abstract

“…Numbers of Tregs in plaques or in the blood of CVD patients appear to decrease in response to various therapeutic interventions, including drug-eluting stent placement (148) and statin therapy (149). Overall, the data suggest that increasingly abundant Tregs may be a feasible goal for pharmacologic immuno modulation of patients who are at risk of complications of unstable plaques.…”

Section: Regulation Of Proatherogenic Adaptive Immune Responsesmentioning

confidence: 99%

The Influence of Innate and Adaptive Immune Responses on Atherosclerosis

Witztum

Lichtman

2014

Annu. Rev. Pathol. Mech. Dis.

236

191

View full text Add to dashboard Cite

Both the chronic development of atherosclerotic lesions and the acute changes in lesion phenotype that lead to clinical cardiovascular events are significantly influenced by the innate and adaptive immune responses to lipoprotein deposition and oxidation in the arterial wall. The rapid pace of discovery of mechanisms of immunologic recognition, effector functions, and regulation has significantly influenced the study of atherosclerosis, and our new knowledge is beginning to affect how we treat this ubiquitous disease. In this review, we discuss recent advances in our understanding of how innate and adaptive immunity contribute to atherosclerosis, as well as therapeutic opportunities that arise from this knowledge.

show abstract

“…Only low numbers of CD4 + Foxp3 + T cells have been identified in human atherosclerotic plaques at various stages of development (117), but increased numbers of carotid plaque Foxp3 + CD3 + T cells have been associated with symptomatic disease (118). The enumeration of Foxp3 + CD4 + T cells in the blood reveals a generalized trend toward decreased numbers of blood Tregs in patients with clinically active CVD compared with controls (48,119,120) and increased Treg numbers in the blood or lesions in response to various therapeutic interventions including statins (121)(122)(123). The effects of statins on Treg development may contribute to the drugs' well-documented pleiotropic anti-inflammatory effects and are in need of further study (124).…”

Section: Regulation Of Proatherogenic Adaptive Immune Responsesmentioning

confidence: 99%

Adaptive immunity in atherogenesis: new insights and therapeutic approaches

Lichtman¹,

Binder²,

Tsimikas³

et al. 2013

J. Clin. Invest.

170

171

View full text Add to dashboard Cite

Many remarkable advances have improved our understanding of the cellular and molecular events in the pathogenesis of atherosclerosis. Chief among these is the accumulating knowledge of how the immune system contributes to all phases of atherogenesis, including well-known inflammatory reactions consequent to intimal trapping and oxidation of LDL. Advances in our understanding of the innate and adaptive responses to these events have helped to clarify the role of inflammation in atherogenesis and suggested new diagnostic modalities and novel therapeutic targets. Here we focus on recent advances in understanding how adaptive immunity affects atherogenesis.

show abstract

CD4+CD25highCD127low regulatory T cells in patients with stable angina and their dynamics after intracoronary sirolimus-eluting stent implantation

Cited by 5 publications

References 29 publications

Rapamycin: A Bacteria-Derived Immunosuppressant That Has Anti-atherosclerotic Effects and Its Clinical Application

Rapamycin: A Bacteria-Derived Immunosuppressant That Has Anti-atherosclerotic Effects and Its Clinical Application

The Influence of Innate and Adaptive Immune Responses on Atherosclerosis

Adaptive immunity in atherogenesis: new insights and therapeutic approaches

Contact Info

Product

Resources

About